L-Leucine (DB00149): A Comprehensive Monograph on its Pharmacology, Metabolism, and Clinical Utility

Executive Summary

L-Leucine is an essential, branched-chain amino acid (BCAA) that occupies a unique and central position in human physiology, functioning not only as a fundamental substrate for protein synthesis but also as a potent signaling molecule that governs cellular metabolism and growth. This monograph provides a comprehensive analysis of L-Leucine, synthesizing data from foundational biochemistry to contemporary clinical research. Its primary mechanism of action involves the direct activation of the mechanistic Target of Rapamycin Complex 1 (mTORC1), a master regulator of anabolism. This insulin-independent signaling capacity distinguishes Leucine from other amino acids and underpins its profound effects on skeletal muscle homeostasis, where it dually stimulates muscle protein synthesis and inhibits protein breakdown.

Clinically, Leucine is an indispensable component of parenteral nutrition formulations, where it is critical for maintaining nitrogen balance and preventing muscle catabolism in patients under severe metabolic stress. Its role as a therapeutic agent is most extensively studied in the context of age-related sarcopenia, where it can help overcome anabolic resistance, particularly when administered as part of a complete protein source and in conjunction with other key nutrients like Vitamin D. While widely used in sports nutrition to enhance muscle growth and recovery, its efficacy in this domain is highly dependent on the individual's training status and background protein intake. Investigational studies are exploring its potential in diverse areas, including obesity, rare hematological disorders, and post-traumatic recovery.

The pharmacokinetic profile of Leucine is characterized by saturable, carrier-mediated transport and significant first-pass metabolism in the intestine, with cellular uptake and tissue-specific effects being tightly regulated by a family of solute carrier transporters. Its catabolism is strictly ketogenic, yielding acetyl-CoA and acetoacetate, and also produces the bioactive metabolite β-hydroxy-β-methylbutyrate (HMB), which may mediate some of its effects. Leucine is generally safe at recommended doses, though high intake can lead to metabolic disturbances and potential toxicity. Its regulatory status is multifaceted, being classified as Generally Recognized as Safe (GRAS) for food and supplement use, while its derivative, N-Acetyl-L-Leucine (levacetylleucine), recently achieved FDA approval as a targeted therapy for a rare neurological disease, illustrating a modern pathway from nutrient to pharmaceutical. Future research is focused on optimizing its therapeutic application, elucidating the roles of its metabolites and transporters, and further defining its long-term impact on metabolic health.

Compound Identification and Physicochemical Profile

The precise identification and characterization of L-Leucine's physical and chemical properties are fundamental to understanding its biological function, stability, and formulation in both nutritional and pharmaceutical contexts.

Nomenclature and Identifiers

L-Leucine is recognized globally across scientific, regulatory, and commercial domains by a variety of names and unique identifiers. This extensive cataloging reflects its ubiquitous presence and importance in chemistry, food science, metabolomics, and pharmacology.

• Generic Name: Leucine [1]
• Systematic (IUPAC) Name: (2S)-2-Amino-4-methylpentanoic acid [1]
• Common Synonyms: L-Leucine, (S)-(+)-Leucine, L-Leucin, Leu, H-Leu-OH, L-α-Aminoisocaproic acid, 2-Amino-4-methylvaleric acid [1]
• DrugBank ID: DB00149 [1]
• CAS Number: 61-90-5 [1]
• PubChem CID: 6106 [2]
• ChEBI ID: CHEBI:15603 [2]
• FDA UNII: GMW67QNF9C [3]
• European Community (EC) Number: 200-522-0 [4]
• FEMA Number: 3297 [3]
• JECFA Number: 1423 [3]
• Human Metabolome Database (HMDB) ID: HMDB0000687 [5]

The presence of identifiers from bodies such as the Flavor and Extract Manufacturers Association (FEMA) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) alongside pharmacological identifiers like its DrugBank ID highlights the molecule's dual identity.[3] It is not merely a drug or a nutrient but a foundational biological compound whose properties and applications are studied and regulated across multiple disciplines. This multifaceted identity is central to understanding its complex regulatory status and its function as both a bulk nutritional component and a specific pharmacological signaling agent.

Molecular and Structural Properties

L-Leucine is an α-amino acid, defined by an α-amino group, an α-carboxylic acid group, and a characteristic side chain attached to the α-carbon.[6]

• Chemical Formula: C6​H13​NO2​ [1]
• Molecular Weight:
• Average: 131.17–131.18 g/mol [1]
• Monoisotopic: 131.094628665 Da [1]
• Structure: The side chain is an isobutyl group (−CH2​CH(CH3​)2​), which classifies Leucine as a non-polar, aliphatic, branched-chain amino acid (BCAA), along with isoleucine and valine.[1]
• Stereochemistry: As with nearly all proteinogenic amino acids, the biologically active form is the L-enantiomer, designated as L-Leucine or (S)-Leucine.[5] Its optical isomer, D-Leucine, exists but is not incorporated into proteins in mammals.[7] Other structural isomers, such as L-tert-Leucine, also exist but have different biological properties.[8]

Physicochemical Characteristics

The physical properties of L-Leucine dictate its behavior in aqueous solutions, its stability in formulations, and its interactions within biological systems.

• Physical Description: It appears as white, shiny hexahedral crystals or a white to off-white crystalline powder. It is odorless and possesses a slightly bitter taste.[3]
• Solubility: L-Leucine has moderate solubility in water, reported as 22.4 g/L at 20°C. It is more soluble in acidic solutions, such as 1 M HCl (50 mg/mL).[3]
• Melting Point: It does not have a sharp melting point; it sublimates at 145–148°C and melts with decomposition at temperatures greater than 300°C.[3]
• Stability: The compound is sensitive to moisture and light. It is chemically incompatible with strong oxidizing agents.[3]
• Acidity (pKa): The carboxylic acid group has a pKa​ of 2.328 at 25°C.[3]
• Lipophilicity (LogP): The octanol-water partition coefficient (LogP) is 0.80, indicating a moderate degree of lipophilicity conferred by its isobutyl side chain.[3]

A consolidated view of these properties is presented in Table 1.

Table 1. Physicochemical and Identification Properties of L-Leucine

Property	Value	Source(s)
IUPAC Name	(2S)-2-Amino-4-methylpentanoic acid	1
CAS Number	61-90-5	1
DrugBank ID	DB00149	1
PubChem CID	6106	2
Chemical Formula	C6​H13​NO2​	1
Average Molecular Weight	131.17 g/mol	1
Physical Form	White crystalline powder or shiny crystals	3
Melting Point	>300 °C (decomposes)	3
Water Solubility	22.4 g/L (at 20°C)	3
pKa	2.328 (at 25°C)	3
LogP	0.80	3
Stability	Moisture and light sensitive	3

Pharmacodynamics: Molecular Mechanisms and Physiological Impact

L-Leucine's physiological effects extend far beyond its structural role as a protein constituent. It functions as a primary signaling molecule, or nutraceutical, that directly informs the cell of nutrient availability, thereby orchestrating a complex network of metabolic responses. Its most profound and well-characterized role is as a potent activator of anabolic pathways, particularly within skeletal muscle.

The mTORC1 Signaling Nexus: Leucine as a Master Anabolic Regulator

The cornerstone of Leucine's signaling function is its ability to activate the mechanistic Target of Rapamycin Complex 1 (mTORC1), a serine/threonine protein kinase that serves as a central hub for integrating signals from growth factors, energy status, and amino acids to control cell growth and protein synthesis.[9] Among all amino acids, Leucine is the most powerful activator of this pathway.[6]

Upstream Sensing Mechanisms

Cells have evolved sophisticated and redundant mechanisms to specifically sense intracellular Leucine concentrations and transmit this signal to mTORC1, which resides on the lysosomal surface.

• The Sestrin2 Pathway: Under conditions of Leucine deprivation, the protein Sestrin2 binds to and inhibits the GATOR2 complex. GATOR2 is a positive regulator of mTORC1. Upon Leucine binding directly to Sestrin2, this inhibition is relieved. The now-active GATOR2 complex inhibits the GATOR1 complex, which functions as a GTPase-activating protein (GAP) for the RagA/B GTPases. This intricate series of inhibitions ultimately allows the Rag GTPase heterodimer to adopt an active conformation (RagA/B-GTP, RagC/D-GDP), which recruits mTORC1 to the lysosome for its activation by the Rheb GTPase.[6]
• The Leucyl-tRNA Synthetase (LARS) Pathway: In addition to its canonical role in charging tRNA with Leucine for protein synthesis, LARS also functions as a direct intracellular sensor of Leucine. When Leucine levels are high, Leucine-bound LARS translocates to the lysosome and acts as a GAP for RagD. This action promotes the active Rag heterodimer conformation required for mTORC1 activation, providing a parallel and complementary sensing mechanism.[6]

Downstream Effectors of mTORC1

Once activated at the lysosome, mTORC1 phosphorylates a suite of downstream targets that collectively promote anabolism and suppress catabolism. The two most critical effectors for protein synthesis are:

• p70 S6 Kinase 1 (p70S6K1): mTORC1-mediated phosphorylation of p70S6K1 leads to its activation. Active p70S6K1 then phosphorylates several substrates, including the ribosomal protein S6, which enhances the translation of a specific class of mRNAs known as 5'-terminal oligopyrimidine (5'TOP) tracts. These mRNAs primarily encode components of the translational machinery itself, such as ribosomal proteins and elongation factors, thus creating a positive feedback loop that amplifies the cell's capacity for protein synthesis.[14]
• 4E-Binding Protein 1 (4E-BP1): In its hypophosphorylated state, 4E-BP1 binds tightly to the eukaryotic initiation factor 4E (eIF4E), sequestering it and preventing the formation of the eIF4F complex. This complex is essential for the initiation of cap-dependent mRNA translation, the primary mechanism for translating most cellular proteins. mTORC1 phosphorylates 4E-BP1 at multiple sites, causing it to release eIF4E. The liberated eIF4E can then participate in forming the eIF4F complex, which recruits the 40S ribosomal subunit to the mRNA, thereby initiating translation.[12]

A defining feature of Leucine's action is its ability to stimulate this entire cascade independently of growth factors like insulin.[12] While insulin signaling through the PI3K-Akt pathway also activates mTORC1 (by inhibiting the TSC1/2 complex), Leucine provides a direct, nutrient-driven input, allowing cells to mount an anabolic response to amino acid availability even in the absence of high insulin levels.

Regulation of Skeletal Muscle Homeostasis: The Dual Anabolic/Anti-Catabolic Effect

Skeletal muscle is a primary target of Leucine's action, where it exerts a powerful influence on protein turnover by coordinately stimulating muscle protein synthesis (MPS) and inhibiting muscle protein breakdown (MPB).[1]

• Stimulation of Muscle Protein Synthesis: The activation of the mTORC1-p70S6K1/4E-BP1 axis is the principal mechanism by which Leucine triggers a robust increase in the rate of MPS.[9] This makes Leucine a critical nutrient for muscle growth (hypertrophy) and repair following exercise or injury.
• Inhibition of Muscle Protein Breakdown: Leucine also possesses anti-catabolic properties, helping to prevent the net loss of muscle protein that occurs during periods of trauma, severe stress, or immobilization.[1] This effect is partly mediated by mTORC1, which can suppress autophagy (a major cellular degradation process) by phosphorylating and inhibiting the ULK1 complex. Furthermore, some of Leucine's anti-catabolic effects may be mediated by its metabolite, HMB, which has been shown to attenuate MPB through mechanisms that appear to be independent of insulin.[16]

This dual action—simultaneously turning on the synthetic machinery and turning down the degradative machinery—positions Leucine as the most potent single nutritional regulator of muscle mass.

Role in Systemic Energy and Glucose Metabolism

Leucine's influence is not confined to muscle tissue; it also plays a significant role in regulating systemic energy and substrate metabolism.

• Ketogenic Fate and Energy Production: Leucine is classified as a strictly ketogenic amino acid because its carbon skeleton cannot be used to synthesize glucose (gluconeogenesis). Its complete catabolism yields acetyl-CoA and acetoacetyl-CoA.[1] These molecules can enter the tricarboxylic acid (TCA) cycle in mitochondria to generate ATP, or they can be used by the liver to produce ketone bodies, which serve as an alternative energy source for extrahepatic tissues during periods of fasting or low carbohydrate availability.[6] The catabolism of Leucine in muscle yields energy intermediates NADH and FADH2, contributing directly to local ATP generation.[1]
• Insulin Secretion and Glucose Homeostasis: Leucine acts as a secretagogue, stimulating the release of insulin from pancreatic β-cells.[3] This effect is particularly pronounced in the presence of glucose. The mechanism involves Leucine's metabolism within the β-cell mitochondria, coupled with its ability to allosterically activate the enzyme glutamate dehydrogenase (GDH). This increases mitochondrial metabolism and ATP production, leading to the closure of ATP-sensitive potassium channels and subsequent insulin vesicle exocytosis.[14] This insulinotropic effect complements its direct anabolic actions in muscle by promoting glucose uptake and further enhancing the anabolic environment.[12]

Comparative Analysis with Isoleucine and Valine

While Leucine, isoleucine, and valine are collectively known as BCAAs and share the initial enzymatic steps of their catabolism, their ultimate metabolic fates and signaling capabilities are distinct.

• Divergent Metabolic Fates: The three BCAAs are all transaminated by BCAT and oxidatively decarboxylated by the BCKDH complex.[1] After this common start, their pathways diverge:
• Leucine: Is strictly ketogenic, yielding acetyl-CoA and acetoacetyl-CoA.[1]
• Isoleucine: Is both ketogenic and glucogenic, yielding acetyl-CoA and propionyl-CoA (which can be converted to the TCA cycle intermediate succinyl-CoA).[1]
• Valine: Is strictly glucogenic, yielding propionyl-CoA.[1]
• Differential Signaling Properties: Leucine is the primary signaling BCAA. Studies demonstrate that at physiological concentrations, only Leucine is capable of robustly activating mTORC1 and stimulating p70S6K1 phosphorylation. Isoleucine and valine do not share this potent signaling capacity.[14]
• Metabolic Antagonism and Balance: There is a competitive interaction among the BCAAs for transport and metabolism. A high intake of Leucine can accelerate the oxidation of isoleucine and valine, leading to a decrease in their plasma concentrations.[18] This underscores the importance of a balanced intake of all three BCAAs for optimal protein metabolism, as an excess of Leucine could potentially create a functional deficiency of the others.

The profound acute effect of Leucine on MPS, however, presents a clinical paradox. Numerous studies confirm its ability to act as a powerful trigger for protein synthesis.[9] Yet, long-term studies involving chronic supplementation with isolated Leucine often fail to produce the expected gains in muscle mass, particularly in healthy individuals.[20] This discrepancy can be explained by viewing Leucine not as a standalone anabolic agent but as a signal or "trigger." The initiation of MPS by Leucine creates an immediate demand for all essential amino acids (EAAs) to serve as building blocks for the new proteins. If these substrates are not readily available, the synthetic response cannot be sustained. This is supported by preclinical work where free Leucine added to a slowly digested protein failed to augment muscle recovery, while a rapidly digested, Leucine-rich whey protein, which provides a synchronized supply of both the Leucine signal and the full complement of EAA substrates, was effective.[20] This principle is crucial for clinical and nutritional applications, suggesting that Leucine's efficacy is maximized when it is part of a complete and rapidly available EAA source, rather than when taken in isolation.

Pharmacokinetics: A Systemic Journey from Ingestion to Cellular Action

The physiological effects of L-Leucine are contingent upon its absorption from the gut, distribution to target tissues, cellular uptake, and subsequent metabolism. The pharmacokinetic profile of Leucine is actively regulated at multiple levels, influencing its bioavailability and ultimate biological impact.

Absorption

Leucine absorption from dietary protein or supplements occurs predominantly in the small intestine and is governed by carrier-mediated transport systems.[23]

• Site and Efficiency: Approximately 90–95% of amino acid absorption takes place in the small intestine.[23] The process is highly efficient but subject to saturation.
• Saturable, Concentration-Dependent Transport: Leucine uptake across the intestinal brush border is not a passive process but relies on specific amino acid transporters. This transport is saturable, meaning there is a maximum capacity for absorption. At low luminal concentrations (e.g., 1.2 mM), the absorption rate can be as high as 94%. However, at higher, bolus-dose concentrations (e.g., 20 mM, equivalent to about a 3 g dose), the fractional absorption rate can decrease significantly to around 52% as the transporters become saturated.[23]
• Competitive Inhibition: The transporters responsible for Leucine uptake, such as System L transporters, also facilitate the transport of other large neutral amino acids, including the other BCAAs, isoleucine and valine. This leads to competitive inhibition, where the presence of high concentrations of one amino acid can reduce the absorption rate of others competing for the same carrier protein.[23]
• Intestinal First-Pass Metabolism: A notable feature of Leucine pharmacokinetics is a significant first-pass effect within the enterocytes of the small intestine. It is estimated that approximately 30% of the Leucine absorbed from the gut lumen is immediately utilized by the intestinal cells for their own high metabolic needs, including local protein synthesis, energy production (oxidation), and synthesis of transporters and immune molecules. This splanchnic extraction reduces the quantity of ingested Leucine that reaches the portal circulation and becomes systemically available.[23]

Distribution and Cellular Transport

Following absorption and intestinal metabolism, Leucine enters the portal vein. A key feature of BCAA distribution is the bypass of significant first-pass hepatic metabolism. The liver has very low activity of the initial enzyme in BCAA catabolism, branched-chain aminotransferase (BCAT), allowing Leucine to pass through largely unmetabolized into the systemic circulation for distribution to peripheral tissues.[6] The delivery of Leucine from the bloodstream into target cells is a critical, regulated step mediated by specific transporter proteins from the Solute Carrier (SLC) family.

• L-Type Amino Acid Transporter 1 (LAT1/SLC7A5): This is a primary transporter for Leucine into many key tissues. LAT1 is a sodium-independent, obligatory exchanger that facilitates the transport of large neutral amino acids. It is highly expressed in skeletal muscle, at the blood-brain barrier (BBB), and in the placenta.[26] In human skeletal muscle, LAT1 is localized to the sarcolemmal membrane and shows higher expression in fast-twitch (Type II) fibers, which have a high capacity for hypertrophy, suggesting a link between Leucine transport capacity and anabolic potential.[26] The function of LAT1 is essential for normal myogenesis.[30]
• SLC6A15: This sodium-dependent BCAA transporter is expressed specifically in neurons within key brain regions that regulate energy homeostasis, such as the hypothalamus and the nucleus of the solitary tract. It functions as a central sensor for circulating Leucine levels, and its activity is linked to Leucine's effects on appetite and metabolism. Genetic knockout of SLC6A15 in animal models attenuates the anorexic effects of Leucine, highlighting the transporter's critical role in mediating its central actions.[31]
• Bacterial Leucine Transporter (LeuT) as a Model: Much of the structural and mechanistic understanding of human SLC transporters, including those in the SLC6 family, comes from studies of the bacterial homolog LeuT. It is a sodium-dependent symporter with twelve transmembrane helices that operates via a "rocker-switch" mechanism to move Leucine across the membrane, providing a powerful model for human neurotransmitter and amino acid transporters.[32]

The activity and expression of these transporters are not static. They represent key regulatory points that control the flux of Leucine into cells. This implies that the cellular response to Leucine is not solely dependent on its plasma concentration but also on the capacity of the tissue to transport it intracellularly. This transport step can be a rate-limiting factor for Leucine's efficacy, suggesting that modulating transporter function could be a novel strategy to enhance Leucine's anabolic effects.

Metabolism

Leucine metabolism is a complex process that occurs primarily in the mitochondria of peripheral tissues, especially skeletal muscle and adipose tissue. It serves both to generate energy and to produce bioactive signaling molecules.[6]

• Initial Catabolic Steps: The catabolism of all three BCAAs begins with two common enzymatic reactions:

1. Transamination: In the mitochondrial matrix, Leucine's amino group is transferred to α-ketoglutarate by the enzyme mitochondrial branched-chain aminotransferase (BCATm or BCAT2). This reversible reaction yields glutamate and the α-keto acid of Leucine, α-ketoisocaproate (KIC).[1]
2. Oxidative Decarboxylation: KIC is then committed to irreversible catabolism by the branched-chain α-keto acid dehydrogenase (BCKDH) complex. This multi-enzyme complex, located on the inner mitochondrial membrane, catalyzes the oxidative decarboxylation of KIC to form isovaleryl-CoA. This is the rate-limiting and regulated step in Leucine degradation.[1]

• Metabolic Fates of Leucine and its Metabolites:
• Protein Synthesis: The primary fate of dietary Leucine is incorporation into new proteins. In healthy individuals, approximately 80% of an ingested dose is directed towards protein synthesis.[9]
• Ketogenesis (Major Catabolic Pathway): The isovaleryl-CoA produced by BCKDH enters a series of reactions analogous to fatty acid β-oxidation, ultimately yielding the ketogenic products acetyl-CoA and acetoacetate. These cannot be converted to glucose but can be used for ATP synthesis or ketone body formation.[1]
• HMB Synthesis (Minor Pathway): A small fraction, estimated at 5–10%, of the KIC formed from Leucine transamination is shunted into an alternative pathway. In the cytosol of tissues like the liver and kidney, the enzyme α-KIC dioxygenase converts KIC into β-hydroxy-β-methylbutyrate (HMB).[9] HMB is a bioactive metabolite that has been shown to possess anabolic and, most notably, anti-catabolic properties, suggesting it may be responsible for some of the observed effects of Leucine supplementation, particularly the inhibition of muscle protein breakdown.[9]

Excretion

Direct excretion of unmetabolized Leucine is minimal, reflecting its high value to the body as an essential amino acid.

• Mass Balance: Radiolabeling studies in rats provide a clear picture of Leucine's fate. Following an oral dose of 14C-leucine, less than 1% of the radioactivity is recovered in urine and feces.[39]
• Primary Fates: The vast majority of the administered dose is either retained in the body, primarily through incorporation into tissue proteins (approximately 61% recovered in the carcass), or is fully oxidized for energy, with the radiolabeled carbon being released as CO2 (estimated to be about one-third of the dose).[36]
• Urinary Metabolites: The small amount of material that is excreted via urine consists of metabolic byproducts. Novel metabolites identified in rat urine include N-acetyl leucine and glycyl leucine, in addition to HMB, which appears in both plasma and urine following a Leucine dose.[39]

Clinical and Therapeutic Landscape

L-Leucine's unique physiological roles have led to its use and investigation across a wide range of clinical and nutritional settings. Its application spans from established, life-sustaining medical therapies to its widespread use as a nutraceutical for performance enhancement and health maintenance.

Established Medical Use: Parenteral Nutrition

Leucine is a cornerstone of clinical nutrition, where it is an essential and mandatory component of total parenteral nutrition (TPN) solutions. These formulations are administered intravenously to patients who are unable to absorb nutrients through the gastrointestinal tract due to illness, surgery, or trauma.[1]

• Formulations: Leucine is included in numerous commercially available and hospital-compounded amino acid solutions, such as Aminosyn, Clinimix, Freamine, Olimel, and Travasol.[1]
• Clinical Rationale: In critically ill or post-operative patients, the body enters a hypercatabolic state characterized by accelerated muscle protein breakdown. The provision of Leucine in TPN is vital to:
• Maintain Nitrogen Balance: Supply the necessary building blocks to counteract protein loss.
• Prevent Muscle Wasting: Its potent anti-catabolic and anabolic signaling properties help to preserve lean body mass and muscle function during periods of severe stress.[1]
• Support Immune Function and Wound Healing: Provide substrate for the synthesis of acute-phase proteins and support overall recovery.[1]
• Evidence Base: The use of Leucine as part of balanced amino acid solutions in TPN is supported by extensive clinical experience and trials in diverse patient populations, including premature infants, low birth weight infants, sepsis patients, and individuals with proven insufficient enteral resorption, where it has completed Phase 3 trials as part of combination products.[41]

Sarcopenia and Age-Related Anabolic Resistance

Sarcopenia, the progressive loss of skeletal muscle mass, strength, and function with age, is a major public health concern contributing to frailty and loss of independence.[20] A key underlying mechanism is "anabolic resistance," where aging muscle exhibits a blunted protein synthetic response to nutritional stimuli like protein intake.[20] Leucine supplementation has been a primary strategy investigated to overcome this resistance.

• Mechanism of Action: By directly stimulating the mTORC1 pathway, Leucine can act as a powerful signal to "trigger" muscle protein synthesis (MPS), helping to restore the anabolic response in older muscle.[12]
• Evidence from Clinical Trials and Meta-Analyses:
• Acute Effects: Leucine supplementation, either alone or enriching a meal, consistently and significantly increases the acute rate of muscle protein fractional synthesis rate (FSR) in elderly individuals.[19]
• Chronic Effects on Muscle Mass and Strength: The translation of this acute effect into long-term gains is more complex. Multiple systematic reviews and meta-analyses have concluded that supplementation with isolated Leucine does not consistently lead to significant increases in lean body mass or muscle strength over time.[21]
• The Importance of Co-Interventions: The efficacy of Leucine is substantially enhanced when it is part of a multi-component strategy. The most successful interventions combine Leucine with:

1. A Complete Protein Source: Providing a full spectrum of essential amino acids (EAAs) as substrates is critical. Leucine-enriched whey protein is a common and effective formulation.[47]
2. Vitamin D: Co-supplementation with Vitamin D, which is often deficient in the elderly, significantly improves outcomes, particularly for muscle strength and physical performance.[45]
3. Resistance Exercise: The combination of Leucine-enriched protein supplementation with a structured resistance exercise program yields the most robust benefits for muscle mass, strength, and function.[48]

• Recommended Dosing: Based on this evidence, international guidelines for counteracting sarcopenia recommend a dietary strategy that includes 25–30 g of high-quality protein containing approximately 3 g of Leucine at each main meal.[12] Clinical trials have typically used supplemental Leucine doses ranging from 1.2 g to 6 g per day.[52]

Athletic Performance and Recovery

Leucine is one of the most popular dietary supplements in sports nutrition, used by athletes to maximize muscle hypertrophy, accelerate recovery from exercise, and improve performance.[15]

• Physiological Rationale: Intense exercise creates a stimulus for muscle adaptation but also induces muscle damage and protein breakdown. Leucine supplementation, particularly post-exercise, is intended to shift the net protein balance towards anabolism by robustly stimulating MPS and attenuating proteolysis.[15] It may also serve as an energy source during prolonged activity and spare muscle glycogen stores.[15]
• Clinical and Performance Evidence:
• Biochemical Effects: Supplementation can effectively prevent the decline in plasma Leucine levels that occurs after strenuous exercise.[15] Leucine-enriched EAA supplements consumed during or after exercise have been shown to enhance the post-exercise MPS response.[55]
• Performance Outcomes: The evidence for a direct ergogenic effect is mixed. Some studies have shown significant improvements in performance metrics, such as a study in outrigger canoeists where six weeks of Leucine supplementation increased endurance performance and upper body power.[56] Another study in basketball players found that Leucine supplementation significantly improved sprint performance.[54]
• Limitations and Context: However, other studies have failed to find significant benefits, particularly for long-term muscle mass or strength gains in well-trained individuals who are already consuming a diet adequate in protein.[57] This suggests that, similar to its role in sarcopenia, Leucine's effectiveness in athletes is highly context-dependent. It may be most beneficial for promoting recovery from novel or particularly damaging exercise, or in situations where background protein intake is suboptimal.

Investigational and Emerging Applications

The unique metabolic and signaling properties of Leucine have prompted its investigation in a variety of other clinical conditions.

• Obesity and Metabolic Syndrome: Leucine has been studied for its potential to regulate energy balance and improve metabolic health. A completed Phase 2 clinical trial has explored its use for the treatment of obesity.[58] While central administration of Leucine in animal models reduces food intake, this effect is not reliably replicated with oral supplementation in humans.[10] Its effects on adiposity are complex; it may aid fat loss during caloric restriction but has shown paradoxical effects in already-obese models. It may, however, improve glucose homeostasis and insulin sensitivity independent of weight loss.[10]
• Rare Hematological Disorders: Leucine has been investigated in a pilot Phase 1/2 study for the treatment of transfusion-dependent Diamond-Blackfan Anemia (DBA) and Pure Red Cell Aplasia, suggesting a potential role in stimulating erythropoiesis.[59]
• Post-Traumatic Injury: A Phase 0 trial has examined its role in supportive care for protein feeding after trauma, leveraging its well-established anti-catabolic properties to prevent muscle breakdown in hypermetabolic states.[60]
• Phenylketonuria (PKU): Leucine may be beneficial for individuals with PKU, a genetic disorder where the body cannot metabolize the amino acid phenylalanine. Supplementation with other large neutral amino acids like Leucine can help compete with phenylalanine for transport across the blood-brain barrier, potentially reducing its neurotoxic effects.[1]

The diverse clinical applications of Leucine underscore a unifying principle: its efficacy is profoundly dependent on the underlying physiological context. It is not a universal anabolic agent but rather a conditional modulator. Its therapeutic value is most pronounced when there is an anabolic deficit to correct (e.g., critical illness, anabolic resistance of aging) or a specific anabolic opportunity to amplify (e.g., post-exercise recovery). In states of metabolic health and anabolic sufficiency, its effects are often blunted. This principle is essential for guiding its appropriate clinical use and for designing future research to target populations most likely to benefit.

Table 2. Summary of Key Clinical Trials for Leucine Supplementation

Indication	Trial Phase/Design	Key Findings	Dosage Used	Source(s)
Parenteral Nutrition	Phase 3 (as part of combination products)	Established efficacy for nutritional support in various patient populations (e.g., premature infants, sepsis, insufficient enteral resorption).	Varies by formulation	41
Sarcopenia / Elderly Muscle Health	Meta-analysis of 9 RCTs	Significantly increased muscle protein fractional synthesis rate but did not significantly increase lean body mass or leg lean mass.	Varied across studies	21
Sarcopenia (Institutionalized Elderly)	RCT (n=50)	Improved functional performance (walking time) and lean mass index; improved maximum static expiratory force.	6 g/day	61
Obesity	Phase 2 (Completed)	Investigated as a treatment for obesity.	Not specified	58
Diamond-Blackfan Anemia / Pure Red Cell Aplasia	Phase 1/2 (Completed)	Investigated as a treatment for transfusion-dependent anemia.	Not specified	59
Post-Traumatic Injury	Phase 0 (Completed)	Explored for supportive care in protein feeding post-injury.	Not specified	60

Safety Profile, Contraindications, and Drug Interactions

While L-Leucine is an essential nutrient and generally safe when consumed as part of a balanced diet, high-dose supplementation carries potential risks and is contraindicated in certain populations. A thorough understanding of its safety profile is critical for responsible clinical and personal use.

Adverse Effects and Tolerability

At typical supplemental doses, Leucine is generally well-tolerated.[61] When adverse effects occur, they are often mild, dose-related, and gastrointestinal in nature.

• Common Side Effects: The most frequently reported issues include gastrointestinal discomfort such as gas, nausea, bloating, and diarrhea. These effects are more common at higher doses and particularly when Leucine is taken in combination with large amounts of whey protein supplements.[57]
• Metabolic and Neurological Effects:
• Hypoglycemia: High doses of Leucine can stimulate insulin secretion and may lead to low blood sugar (hypoglycemia).[53]
• Fatigue and Incoordination: BCAA supplements, in general, have been associated with side effects of fatigue and loss of motor coordination, warranting caution before activities like driving.[64]
• Amino Acid Imbalance: A crucial metabolic concern with isolated Leucine supplementation is the potential to create an imbalance among the BCAAs. High levels of Leucine can competitively inhibit the transport and increase the oxidation of isoleucine and valine, potentially leading to their depletion and limiting the long-term sustainability of muscle protein synthesis.[18]

Toxicity and Upper Intake Levels

While Leucine toxicity from dietary sources is virtually nonexistent, high-dose supplementation can exceed the body's metabolic capacity, leading to potentially severe adverse effects.

• Tolerable Upper Intake Level (UL): There is no official UL established by regulatory bodies. However, based on available evidence, an unofficial tolerable upper limit for acute dietary intake in healthy adult men has been proposed at 500 mg/kg of body weight per day. For a 70 kg (154 lb) individual, this corresponds to approximately 35 g per day.[6]
• Hyperammonemia: The primary dose-limiting toxicity is hyperammonemia. Doses exceeding 500 mg/kg/day can overwhelm the urea cycle's capacity to detoxify the nitrogen released from Leucine catabolism, leading to a dangerous increase in blood ammonia levels. This can cause elevated ammonia concentrations in the brain, resulting in neurotoxicity, confusion, and other neurological impairments.[6]
• Pellagra: High Leucine intake can interfere with the endogenous synthesis of niacin (Vitamin B3) from the amino acid tryptophan. In individuals with a borderline or deficient niacin status, this can precipitate or worsen the symptoms of pellagra, a deficiency disease characterized by dermatitis, diarrhea, and dementia.[6]

Contraindications and At-Risk Populations

Leucine supplementation is strictly contraindicated or requires extreme caution in several specific populations due to underlying medical conditions.

• Maple Syrup Urine Disease (MSUD): This is an absolute contraindication. MSUD is a rare inborn error of metabolism caused by a deficiency in the BCKDH enzyme complex. Individuals with MSUD cannot break down BCAAs, leading to the accumulation of Leucine, isoleucine, valine, and their respective α-keto acids to toxic levels. This causes a characteristic sweet odor in the urine, severe neurological damage, seizures, and developmental delays if untreated.[1]
• Amyotrophic Lateral Sclerosis (ALS): BCAA supplementation has been associated with an increased risk of lung failure and higher mortality in patients with ALS and should be avoided.[64]
• Pregnancy and Breastfeeding: Due to a lack of sufficient safety data, Leucine supplementation is not recommended during pregnancy or while breastfeeding.[53]
• Chronic Kidney or Liver Disease: Patients with impaired renal or hepatic function may have a reduced capacity to metabolize amino acids and clear nitrogenous waste. Leucine supplementation should be used with caution and only under the guidance of a physician.[62]
• Pre-Surgery: Because of its potential to affect blood glucose levels, Leucine supplementation should be discontinued at least two weeks before any scheduled surgery to avoid interference with perioperative glycemic control.[64]

Clinically Significant Interactions

Leucine can interact with certain medications and nutrients, potentially altering their efficacy or increasing the risk of adverse effects.

• Antidiabetic Medications: Due to its insulinotropic and hypoglycemic effects, Leucine can potentiate the action of insulin and other oral antidiabetic drugs. This combination increases the risk of severe hypoglycemia. Patients with diabetes using Leucine supplements must monitor their blood glucose levels closely.[57]
• Levodopa: Leucine competes with Levodopa (a primary medication for Parkinson's disease) for transport across both the intestinal wall and the blood-brain barrier via the LAT1 transporter. This competition can significantly reduce the absorption and central bioavailability of Levodopa, thereby diminishing its therapeutic effectiveness.[57]
• Vitamins B3 (Niacin) and B6: As mentioned, high Leucine intake can impair the conversion of tryptophan to niacin. It may also negatively impact Vitamin B6 status.[57]
• PDE5 Inhibitors (e.g., Sildenafil): Preclinical animal studies suggest that Leucine may enhance the effects of phosphodiesterase type 5 inhibitors. The clinical relevance of this interaction in humans has not been established.[57]

Table 3. L-Leucine Safety Profile: Contraindications, Warnings, and Interactions

Category	Condition/Substance	Nature of Risk/Interaction	Source(s)
Contraindications	Maple Syrup Urine Disease (MSUD)	Inability to metabolize Leucine leads to toxic accumulation and severe neurological damage.	1
	Amyotrophic Lateral Sclerosis (ALS)	Associated with lung failure and increased mortality in ALS patients.	64
Precautions/Warnings	Diabetes Mellitus	Increased risk of hypoglycemia due to Leucine's effects on insulin and blood sugar.	57
	Pregnancy and Breastfeeding	Insufficient safety data; supplementation should be avoided.	53
	Chronic Kidney or Liver Disease	Impaired metabolism and clearance; use only under medical supervision.	62
	Pre-Surgery	Potential interference with blood glucose control; discontinue 2 weeks prior.	64
Drug/Nutrient Interactions	Antidiabetic Medications (e.g., Insulin)	Additive hypoglycemic effect, increasing risk of dangerously low blood sugar.	57
	Levodopa	Competitive inhibition of absorption and transport, reducing therapeutic efficacy.	57
	Niacin (Vitamin B3) & Vitamin B6	High Leucine intake interferes with niacin production from tryptophan and may affect B6 status.	57

Regulatory and Nutraceutical Status

The regulatory classification of L-Leucine is multifaceted, reflecting its dual nature as an essential nutrient ubiquitous in the food supply and a bioactive compound with specific pharmacological effects. This has led to its regulation under different frameworks depending on its intended use and formulation.

FDA Status and Food Use

In the United States, L-Leucine is primarily regulated as a food substance and dietary supplement ingredient.

• Code of Federal Regulations (CFR): L-Leucine is explicitly listed in 21 CFR 172.320, which affirms that amino acids may be safely used in food as nutrient supplements in accordance with good manufacturing practices.[3]
• Generally Recognized as Safe (GRAS): L-Leucine holds GRAS status for its use as a flavor enhancer, flavoring agent, and nutrient supplement.[66] This status is based on a history of safe consumption in food. A specific GRAS notification (GRN 000523) further supports its intended use as an added ingredient in products like meal replacement beverages, sports drinks, and nutrition bars, at levels designed to provide 1.5 to 3 g of L-Leucine per serving.[68]
• Food vs. Drug Distinction: The regulatory line between a dietary supplement and a drug is determined by marketing and intended use. When marketed for its nutritional value to supplement the diet, Leucine is considered a food. However, if it were marketed with claims to diagnose, treat, cure, or prevent a specific disease, it would be classified and regulated as a drug, requiring a rigorous approval process.[67]

Pharmaceutical Formulations and Derivatives

Beyond its role as a supplement, Leucine is an approved component of prescription medical products, and its chemical derivatives are emerging as novel pharmaceuticals.

• Parenteral Nutrition: As previously detailed, L-Leucine is an approved and essential ingredient in numerous prescription-only TPN solutions used for medical nutrition therapy.[1]
• N-Acetyl-L-Leucine (Levacetylleucine): The development of this Leucine derivative provides a clear example of the pathway from a nutrient to a targeted pharmaceutical. This modification alters the molecule's properties, allowing for its development as a distinct therapeutic entity.
• FDA Approval: In a landmark decision in September 2024, the U.S. Food and Drug Administration (FDA) approved Aqneursa (levacetylleucine) as the first stand-alone therapy for treating the neurological manifestations of Niemann-Pick disease type C (NPC), a rare, fatal genetic disorder.[69] The approval was based on a pivotal clinical trial demonstrating a significant improvement in neurological symptoms.[69]
• Investigational Drug Status: N-Acetyl-L-Leucine (investigational name IB1001) is also being actively investigated under an Investigational New Drug (IND) application for other rare neurological disorders, such as Ataxia-Telangiectasia (A-T), with clinical trials approved by the FDA.[71]
• Pharmacological Rationale: The specific development of the L-enantiomer (levacetylleucine) was driven by pharmacokinetic studies on the racemic mixture (N-Acetyl-DL-Leucine). These studies revealed significant differences in the handling of the L- and D-enantiomers, with the L-enantiomer being the primary active moiety, thus justifying its development as a purified drug product.[73]

The trajectory of Leucine and its derivative, levacetylleucine, serves as a compelling illustration of a modern "nutraceutical-to-pharmaceutical" pipeline. This process begins with a deep scientific understanding of a bioactive nutrient's molecular mechanism—in this case, Leucine's profound effects on cellular metabolism and signaling. By applying medicinal chemistry principles to modify the original molecule, its pharmacokinetic and pharmacodynamic properties can be optimized for a specific therapeutic purpose. This modified compound is then subjected to the same rigorous clinical trial and regulatory review process as any conventional new drug. The successful approval of levacetylleucine for NPC validates this approach, demonstrating how foundational nutritional science can be a fertile ground for the discovery and development of novel, targeted medicines for serious diseases. This paradigm suggests that other essential nutrients with potent signaling capabilities could serve as scaffolds for future drug development, blurring the traditional lines between nutrition and pharmacology.

Conclusion and Future Directions

L-Leucine is unequivocally more than a simple building block of protein. It is a pleiotropic signaling molecule that functions as a primary sensor of nutrient availability, wielding significant control over cellular anabolism and systemic metabolism. Its central role as the most potent activator of the mTORC1 pathway establishes it as a master regulator of muscle protein synthesis. However, a comprehensive review of the evidence reveals that its physiological effects are powerful but highly conditional. The clinical and nutritional efficacy of Leucine is not absolute but is instead governed by the "context-is-king" principle; its ability to produce a beneficial outcome is profoundly dependent on the underlying physiological state of the individual, such as the presence of anabolic resistance, catabolic stress, or the availability of other essential nutrients.

The "trigger hypothesis" provides a crucial framework for understanding this context dependency: Leucine acts as a potent signal to initiate protein synthesis, but this anabolic response can only be sustained if a full complement of other essential amino acids is concurrently available to serve as substrates. This explains why Leucine supplementation is most effective when delivered as part of a complete, high-quality protein or EAA mixture, and why isolated Leucine often fails to translate acute increases in muscle protein synthesis into long-term gains in lean mass.

The established role of Leucine in parenteral nutrition is undisputed, where it is essential for mitigating the hypercatabolic state of critical illness. In the management of sarcopenia, it represents a promising but incomplete solution; its true potential is realized as part of a multi-modal strategy that includes adequate total protein, Vitamin D, and resistance exercise. In sports nutrition, its benefits are most likely realized in optimizing post-exercise recovery rather than as a primary driver of hypertrophy in well-nourished athletes. The successful development and FDA approval of its derivative, levacetylleucine, for Niemann-Pick disease type C heralds a new era, demonstrating a viable pipeline from a bioactive nutrient to a targeted pharmaceutical for rare diseases.

Despite extensive research, several key questions remain, which should guide future investigations:

• Optimization of Therapeutic Strategies: Further clinical trials are needed to refine the optimal dosing, timing, and formulation of Leucine for specific populations. This includes determining the ideal Leucine-to-EAA ratio for sarcopenia and the precise peri-exercise window for athletic recovery.
• Elucidating the Role of Metabolites: The bioactive metabolite HMB possesses potent anti-catabolic properties that may be responsible for a significant portion of Leucine's benefits. Head-to-head clinical trials comparing the long-term effects of equimolar Leucine and HMB on muscle mass and function are needed to clarify their respective roles.
• Cellular Transporters as Novel Drug Targets: The discovery that cellular transporters like LAT1 and SLC6A15 are rate-limiting gates for Leucine's action opens an exciting new therapeutic frontier. Research into small molecules that can upregulate the expression or activity of these transporters in a tissue-specific manner could lead to novel strategies for sensitizing muscle to the anabolic effects of Leucine, potentially achieving greater efficacy at lower doses.
• Long-Term Metabolic Safety: While generally safe, elevated circulating BCAA levels have been associated with insulin resistance in epidemiological studies. Long-term, prospective studies are required to definitively assess the impact of chronic, high-dose Leucine supplementation on the risk of developing metabolic syndrome and type 2 diabetes.

In conclusion, L-Leucine stands as a cornerstone of metabolic regulation. Its journey from a basic nutrient to a sophisticated signaling molecule, and now to a precursor for an approved pharmaceutical, highlights the immense potential that lies at the intersection of nutrition and pharmacology. Continued exploration of its complex signaling networks, bioactive metabolites, and the transport systems that govern its action will be essential to fully harness its therapeutic potential for human health.

Works cited

1. Leucine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149
2. CAS RN 61-90-5 - Fisher Scientific, accessed September 5, 2025, https://www.fishersci.com/us/en/browse/cas/61-90-5
3. L-Leucine | 61-90-5 - ChemicalBook, accessed September 5, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8742186.htm
4. L-Leucine (isopropyl-D₇, 98%) - Cambridge Isotope Laboratories, DLM-4212-1, accessed September 5, 2025, https://isotope.com/silac-reagents-and-sets/l-leucine-isopropyl-d7-dlm-4212-1
5. L-Leucine | C6H13NO2 | CID 6106 - PubChem, accessed September 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/L-Leucine
6. Leucine - Wikipedia, accessed September 5, 2025, https://en.wikipedia.org/wiki/Leucine
7. D-Leucine | C6H13NO2 | CID 439524 - PubChem, accessed September 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/D-Leucine
8. L-tert-Leucine | C6H13NO2 | CID 164608 - PubChem, accessed September 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/3-Methyl-l-valine
9. The role of leucine and its metabolites in protein and energy ..., accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/26255285/
10. Reviewing the Effects of l-Leucine Supplementation in the ..., accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4446786/
11. Research progress in the role and mechanism of Leucine in regulating animal growth and development - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10691278/
12. Where to Find Leucine in Food and How to Feed Elderly With ..., accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7874106/
13. Leucine - Metabolite of the month - biocrates life sciences ag, accessed September 5, 2025, https://biocrates.com/leucine/
14. Metabolic Regulation by Leucine of Translation Initiation Through the mTOR-Signaling Pathway by Pancreatic β-Cells | Diabetes, accessed September 5, 2025, https://diabetesjournals.org/diabetes/article/50/2/353/13411/Metabolic-Regulation-by-Leucine-of-Translation
15. Leucine supplementation and intensive training - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/10418071/
16. Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism - PMC, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3690694/
17. What are Leucine and Isoleucine? - News-Medical, accessed September 5, 2025, https://www.news-medical.net/life-sciences/What-are-Leucine-and-Isoleucine.aspx
18. (PDF) Branched-chain amino acid interactions with reference to amino acid requirements in adult men: Leucine metabolism at different valine and isoleucine intakes - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/21296688_Branched-chain_amino_acid_interactions_with_reference_to_amino_acid_requirements_in_adult_men_Leucine_metabolism_at_different_valine_and_isoleucine_intakes
19. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia - PMC, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1819434/
20. Leucine: a nutrient 'trigger' for muscle anabolism, but what more? - PMC, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3447149/
21. The effectiveness of leucine on muscle protein synthesis, lean body ..., accessed September 5, 2025, https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effectiveness-of-leucine-on-muscle-protein-synthesis-lean-body-mass-and-leg-lean-mass-accretion-in-older-people-a-systematic-review-and-metaanalysis/3EC91F121380499B37781A1E03515900
22. Efficacy and Safety of Leucine Supplementation in the Elderly - PMC, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5118760/
23. An exploration of the movement of amino acids from the digestive ..., accessed September 5, 2025, https://nulivscience.com/absorption-amino-acids-digestive-tract-movement-systemic-circulation/
24. Primary Roles of Branched Chain Amino Acids (BCAAs) and Their Metabolism in Physiology and Metabolic Disorders - MDPI, accessed September 5, 2025, https://www.mdpi.com/1420-3049/30/1/56
25. The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology - MDPI, accessed September 5, 2025, https://www.mdpi.com/1422-0067/23/7/4022
26. Characterisation of L-Type Amino Acid Transporter 1 (LAT1 ..., accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5793251/
27. The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health - Frontiers, accessed September 5, 2025, https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2018.00243/full
28. Concentration-dependent uptake of [¹³C6, ¹⁵N]-L-leucine without... - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/figure/Concentration-dependent-uptake-of-C6-N-L-leucine-without-inhibitor-with-5-M_fig4_359551540
29. LAT1 - Transporters - Solvo Biotechnology, accessed September 5, 2025, https://www.solvobiotech.com/transporters/lat1
30. The role of L-type amino acid transporter 1 (Slc7a5) during in vitro myogenesis, accessed September 5, 2025, https://journals.physiology.org/doi/abs/10.1152/ajpcell.00162.2021
31. Involvement of the Neutral Amino Acid Transporter SLC6A15 and ..., accessed September 5, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0068245
32. Bacterial Leucine Transporter - Wikipedia, accessed September 5, 2025, https://en.wikipedia.org/wiki/Bacterial_Leucine_Transporter
33. en.wikipedia.org, accessed September 5, 2025, https://en.wikipedia.org/wiki/Bacterial_Leucine_Transporter#:~:text=Leucine%20transporter%2C%20like%20the%20neurotransmitter,details%20of%20these%20nerve%20proteins.
34. Learn: Structural Biology Highlights: Bacterial Leucine Transporter, LeuT - PDB-101, accessed September 5, 2025, https://pdb101.rcsb.org/learn/structural-biology-highlights/bacterial-leucine-transporter-leut
35. The role of branched-chain amino acids and their downstream metabolites in mediating insulin resistance - Frontiers Publishing Partnerships, accessed September 5, 2025, https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences/articles/10.3389/jpps.2024.13040/full
36. A 14C-leucine absorption, distribution, metabolism and excretion ..., accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4412734/
37. Leucine - MetwareBio, accessed September 5, 2025, https://www.metwarebio.com/metabolites-leucine/
38. Overview of Leucine Metabolism - Creative Proteomics, accessed September 5, 2025, https://www.creative-proteomics.com/resource/overview-leucine-metabolism.htm
39. A 14C-leucine absorption, distribution, metabolism and excretion (ADME) study in adult Sprague–Dawley rat reveals β-hydroxy-β-methylbutyrate as a metabolite - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/271389021_A_14C-leucine_absorption_distribution_metabolism_and_excretion_ADME_study_in_adult_Sprague-Dawley_rat_reveals_b-hydroxy-b-methylbutyrate_as_a_metabolite
40. A (14)C-leucine absorption, distribution, metabolism and excretion (ADME) study in adult Sprague-Dawley rat reveals β-hydroxy-β-methylbutyrate as a metabolite - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/25618754/
41. Leucine Completed Phase 3 Trials for Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption Treatment - DrugBank, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149/clinical_trials?conditions=DBCOND0049925&phase=3&purpose=treatment&status=completed
42. Leucine Completed Phase 3 Trials for Infants, Premature / Sepsis / Small for Gestational Age Infants / Newborn, Infant / Low Birth Weight Infants Treatment - DrugBank, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149/clinical_trials?conditions=DBCOND0079856%2CDBCOND0071031%2CDBCOND0164244%2CDBCOND0014127%2CDBCOND0084579&phase=3&purpose=treatment&status=completed
43. Leucine supplementation chronically improves muscle protein synthesis in older adults consuming the RDA for protein - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/221853830_Leucine_supplementation_chronically_improves_muscle_protein_synthesis_in_older_adults_consuming_the_RDA_for_protein
44. Can leucine help with age-related muscle loss? - Study Summary - Examine.com, accessed September 5, 2025, https://examine.com/research-feed/study/9K4zld/
45. The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/35845777/
46. EFFECT OF LEUCINE SUPPLEMENTATION ON PHYSICAL PERFORMANCE, MUSCLE MASS AND QUALITY OF LIFE IN OLDER PEOPLE WITH SARCOPENIA - Oxford Academic, accessed September 5, 2025, https://academic.oup.com/ageing/article-pdf/doi/10.1093/ageing/afac036.667/47365234/afac036.667.pdf
47. Effect of supplementation with leucine alone, with other nutrients or with physical exercise in older people with sarcopenia: a systematic review - Elsevier, accessed September 5, 2025, https://www.elsevier.es/en-revista-endocrinologia-diabetes-nutricion-english-ed--413-articulo-effect-supplementation-with-leucine-alone-S2530018022001706
48. Effects of Leucine Supplementation in Older Adults with Sarcopenia: A Meta-Analysis - MDPI, accessed September 5, 2025, https://www.mdpi.com/2072-6643/17/15/2413
49. Whey Protein, Leucine- and Vitamin-D-Enriched Oral Nutritional Supplementation for the Treatment of Sarcopenia - MDPI, accessed September 5, 2025, https://www.mdpi.com/2072-6643/14/7/1524
50. Effect of Intake of Leucine-Rich Protein Supplement in Parallel with Resistance Exercise on the Body Composition and Function of Healthy Adults - MDPI, accessed September 5, 2025, https://www.mdpi.com/2072-6643/14/21/4501
51. Where to Find Leucine in Food and How to Feed Elderly With Sarcopenia in Order to Counteract Loss of Muscle Mass: Practical Advice - Frontiers, accessed September 5, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2020.622391/full
52. Beneficial Effects of Leucine Supplementation on Criteria for ... - MDPI, accessed September 5, 2025, https://www.mdpi.com/2072-6643/11/10/2504
53. Leucine - Content - Health Encyclopedia - University of Rochester Medical Center, accessed September 5, 2025, https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=19&contentid=Leucine
54. Unraveling the transcriptomic effects of leucine supplementation on muscle growth and performance in basketball athletes | PLOS One - Research journals, accessed September 5, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0316603
55. Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis1–5 - Oxford Academic, accessed September 5, 2025, https://academic.oup.com/ajcn/article/94/3/809/4411863
56. Effects of dietary leucine supplementation on exercise performance - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/16265600/
57. How Leucine Supports Muscle Health and Other Benefits, accessed September 5, 2025, https://www.verywellhealth.com/leucine-uses-benefits-side-effects-dosage-7567617
58. Leucine Completed Phase 2 Trials for Obesity Treatment | DrugBank Online, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149/clinical_trials?conditions=DBCOND0015947&phase=2&purpose=treatment&status=completed
59. Leucine Completed Phase 1 / 2 Trials for Pure Red Cell Aplasia / Congenital Hypoplastic Anemia / DBA Treatment - DrugBank, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149/clinical_trials?conditions=DBCOND0052431%2CDBCOND0052430%2CDBCOND0028424&phase=1%2C2&purpose=treatment&status=completed
60. Leucine Completed Phase 0 Trials for Protein Feeding in Post-traumatic Injury Patients Supportive Care - DrugBank, accessed September 5, 2025, https://go.drugbank.com/drugs/DB00149/clinical_trials?conditions=DBCOND0085292&phase=0&purpose=supportive_care&status=completed
61. Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7230494/
62. Leucine : Indications, Uses, Dosage, Drugs Interactions, Side effects - Medical Dialogues, accessed September 5, 2025, https://medicaldialogues.in/generics/leucine-2725906
63. Leucine - Health Library, accessed September 5, 2025, https://healthlibrary.uwmedicine.org/Search/19,Leucine
64. BRANCHED-CHAIN AMINO ACIDS (BCAA): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 5, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-1005/branched-chain-amino-acids-bcaa
65. Leucine - Memorial Sloan Kettering Cancer Center, accessed September 5, 2025, https://www.mskcc.org/cancer-care/integrative-medicine/herbs/leucine
66. Substances Added to Food (formerly EAFUS) - cfsanappsexternal.fda.gov, accessed September 5, 2025, https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=FoodSubstances&id=LEUCINE
67. Regulation of Amino Acids and Other Dietary Components Associated with Enhanced Physical Performance - NCBI, accessed September 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK209051/
68. GRAS Notices - cfsanappsexternal.fda.gov, accessed September 5, 2025, https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=523
69. Levacetylleucine Receives FDA Approval as Stand-Alone Therapy for Niemann-Pick Disease Type C - Pharmacy Times, accessed September 5, 2025, https://www.pharmacytimes.com/view/levacetylleucine-receives-fda-approval-as-stand-alone-therapy-for-niemann-pick-disease-type-c
70. FDA Approves New Drug to Treat Niemann-Pick Disease, Type C, accessed September 5, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c
71. CLINICAL TRIAL PROTOCOL Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C - ClinicalTrials.gov, accessed September 5, 2025, https://cdn.clinicaltrials.gov/large-docs/39/NCT03759639/Prot_000.pdf
72. FDA Approves Clinical Testing of an Amino Acid in A-T | A-T Children's Project, accessed September 5, 2025, https://atcp.org/fda-approves-clinical-testing-of-an-amino-acid-in-a-t/
73. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. - Department of Pharmacology, accessed September 5, 2025, https://www.pharm.ox.ac.uk/publications/1092645
74. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance | PLOS One, accessed September 5, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229585